Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
Saved in:
Main Authors: | M Rizzo, I Colomer-Asenjo, G Cabello-Molina, S Marín-López, M Sutil-Vega, C Roca-Guerrero, F Taibi-Hajjami, D García-Vega, M Panelo-Rubio, M Bonastre-Thio, A Martínez-Rubio |
---|---|
Format: | article |
Language: | EN |
Published: |
Radcliffe Medical Media
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/13a7748dffbb483bbadb61a818cf6ee8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
by: M Rizzo, et al.
Published: (2020) -
The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
by: Osama A. Amin, et al.
Published: (2021) -
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
by: Mauro Gori, et al.
Published: (2021) -
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
by: Maria Vincenza Polito, et al.
Published: (2020) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021)